Our Pipeline

Advancing a robust pipeline built in-house

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Phase 3

Upcoming Milestones

Fibrosis

Potential best-in-class
ROCK2
Selective Inhibitor
(RXC007)

Find out more

Lead: Idiopathic pulmonary fibrosis (IPF)
Potential: ILD, cancer associated fibrosis

Phase 2a topline data – Q1 2024

Potential first-in-class
GI-targeted

ROCK Inhibitor
(RXC008)

Find out more

Fibrostenotic Crohn’s Disease

CTA submission – end 2023

Oncology

Potential best-in-class
Porcupine Inhibitor

(RXC004)

Find out more

Genetically selected MSS mCRC

Porcupine

Topline data in combination with anti-PD-1 – from H2 2023

Biliary tract cancer and pancreatic cancer

Porcupine2
Discovery Engine

DDR Inhibitor
(Discoidin Domain Receptor)

Find out more

Fibrosis, cancer-associated fibrosis

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Multiple Programmes)

Oncology & fibrosis

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Find out more

Idiopathic pulmonary fibrosis (IPF)

Licensed to AstraZeneca

Pan-RAF Inhibitor
(JZP815)

Find out more

Oncology

Sold to Jazz Pharmaceuticals

MAPK Pathway Target

Oncology

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase

Our Pipeline

Fibrosis

Potential best-in-class
ROCK2
Selective Inhibitor
(RXC007)

Phase 2

Lead: Idiopathic pulmonary fibrosis (IPF)
Potential: ILD, cancer associated fibrosis

Read more

UPCOMING MILESTONES

Phase 2a topline data – Q1 2024

Potential first-in-class
GI-targeted

ROCK Inhibitor
(RXC008)

Preclinical

Fibrostenotic Crohn’s Disease

Read more

UPCOMING MILESTONES

CTA submission – end 2023

Oncology

Potential best-in-class
Porcupine Inhibitor

(RXC004)

Porcupine
Phase 2

Genetically selected MSS mCRC

Read more

UPCOMING MILESTONES

Topline data in combination with anti-PD-1 – from H2 2023

Porcupine2
Phase 2

Biliary tract cancer and pancreatic cancer

Discovery Engine

DDR Inhibitor
(Discoidin Domain Receptor)

Research

Fibrosis, cancer-associated fibrosis

Read more

UPCOMING MILESTONES

Progress programmes – target of 2 IND’s by 2025

Research Targets
(Multiple Programmes)

Research

Oncology & fibrosis

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Preclinical

Idiopathic pulmonary fibrosis (IPF)

Read more

UPCOMING MILESTONES

Licensed to AstraZeneca

Pan-RAF Inhibitor
(JZP815)

Preclinical

Oncology

Read more

UPCOMING MILESTONES

Sold to Jazz Pharmaceuticals

MAPK Pathway Target

Research

Oncology

UPCOMING MILESTONES

Progress Jazz Collaboration

DDR: Discoidin Domain Receptor; RAF: Rapidly accelerated fibrosarcoma; GI: Gastrointestinal; MAPK: Mitogen-activated protein kinase; MSS mCRC: Microsatellite-Stable Metastatic Colorectal Cancer; ROCK: Rho associated protein kinase